Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2021-04-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于公司未弥补亏损达到实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 启迪药业集团股份公司 regarding the company's accumulated losses exceeding one-third of its paid-in capital. It references an audit report by an accounting firm but does not contain the audit report itself. The document discusses the reasons for the losses, measures to address them, and governance improvements. It is a formal disclosure to shareholders and the public about a significant financial condition requiring shareholder approval, but it is not a full financial report or audit report. The document length is under 5,000 characters and serves as an announcement of a financial condition and related board resolutions. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2021-04-29 Chinese
2020年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2020年度股东大会' which translates to '2020 Annual General Meeting'. It contains detailed meeting materials including the agenda, voting procedures, and multiple proposals to be discussed and voted on during the 2020 Annual General Meeting held on May 28, 2021. The content includes the full text and summary of the 2020 Annual Report, the Board of Directors' work report, the Supervisory Board's work report, the 2020 financial statements, profit distribution plan, and a proposal to change the accounting firm. The document is comprehensive and clearly intended as the materials shared during the AGM, not just an announcement or a brief summary. It includes detailed financial data and reports but is structured as meeting materials for the shareholders' meeting. Therefore, the document fits the category of AGM Information (AGM-R).
2021-04-29 Chinese
一季报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of the company, including approval of the 2021 first quarter report and a proposal regarding uncovered losses. The text emphasizes the meeting's compliance with legal and regulatory requirements and the authenticity of the disclosed information. The document length is short (532 characters), and it does not contain the actual financial statements or detailed financial data but rather the approval and audit opinion on the quarterly report. This fits the profile of a Regulatory Filing (RNS) as it is an announcement related to regulatory compliance and meeting resolutions rather than the full interim report itself.
2021-04-29 Chinese
一季报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 启迪药业集团股份公司 regarding resolutions passed at the ninth interim board meeting. It includes approval of the 2021 Q1 report, a proposal about accumulated losses, a change of auditor, and the scheduling of the 2020 annual general meeting. The document references other announcements published elsewhere for full details and states voting results. The document itself is a board meeting resolution announcement, not the full financial report or the AGM materials. It is not a full annual or quarterly report, nor a call transcript or earnings release. It is not a proxy statement or voting results declaration. It is a board/management information announcement about decisions made by the board. The document length is short (1215 characters) and it references other documents for full content, consistent with a board/management information announcement rather than a full report. Therefore, the best classification is Board/Management Information (MANG).
2021-04-29 Chinese
独立董事关于第九届董事会临时会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the proposal to change the company's accounting firm to Lixin Certified Public Accountants. It references regulatory guidelines related to independent directors and audit firm qualifications. The document is short (544 characters) and focuses on governance and audit firm appointment rather than presenting financial data or audit results. It does not contain full audit reports or financial statements, nor is it an announcement of a report publication. Therefore, it fits best as a Board/Management Information filing, as it relates to board-level decisions and recommendations about auditor changes.
2021-04-29 Chinese
独立董事关于第九届董事会临时会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the pre-approval of a proposal to change the company's accounting firm. It discusses the qualifications of the new auditor and the rationale for the change, but it does not contain any financial statements or audit results itself. The document is short (365 characters) and serves as an announcement or opinion related to audit matters rather than a full audit report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit firm change and audit-related approval, but is not a full annual report or audit report with financial data. Confidence is high due to clear content and context. FY 2021
2021-04-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.